Safinamide in Parkinson´s Disease. A retrospective study
Objective: To evaluate the safety of safinamide in Parkinson´s Disease (PD) and determine consequences of direct switch from rasagiline. Background: A wash-out period is recommended…Rasagiline in Chinese patients with early-stage parkinson’s disease: a randomized, double-blind, placebo-controlled, delayed-start trial
Objective: Objective: This randomized, double-blind, placebo-controlled, delayed-start trial aimed to investigate the efficacy in symptom improvement and disease-modifying effect of rasagiline for Chinese patients with…Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson’s disease: Subgroup analyses from a randomized, controlled trial
Objective: Evaluate the efficacy and safety of P2B001 for different subgroups of patients with early Parkinson’s disease (PD). Background: P2B001 is an investigational, fixed low-dose,…P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial
Objective: Evaluate the efficacy and safety of P2B001 compared with its components and with Extended-Release pramipexole (ER-PPX, calibration arm) in untreated PD. Background: P2B001 is…The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)
Objective: To identify the effect of rasagiline on nocturnal hypokinesia based on Nocturnal Hypokinesia Questionnaire (NHQ). Background: Nocturnal hypokinesia refers to the difficulty or the…Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan
Objective: To evaluate the direct and indirect effects of rasagiline on emotional well-being domain of the PDQ-39 in patients with PD by a post-hoc analysis…The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent rasagiline use (CRU). Background: OPC, a once-daily COMT inhibitor,…Rasagiline as Adjunctive Therapy Induced Impulse Control Disorders in Parkinson’s Disease
Objective: In recent years there are an increasing number of impulse control disorders (ICDs), such as pathologic gambling, hypersexuality, compulsive shopping, compulsive eating, punding and…Slow Release Fixed Dose Combination of Low Doses Pramipexole and Rasagiline (P2B001) for the Treatment of Early Parkinson’s Disease (PD).
Objective: Evaluation of the efficacy and safety of a slow release low dose combination of pramipexole (PPX) and rasagiline (RAS) (P2B001) in a prospective double-blind…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.